Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1982;13(3):174-5.
doi: 10.1007/BF00205383.

Regional Immunotherapy in Resectable Squamous Cell Lung Carcinoma. Analysis of a Randomized Study

Clinical Trial

Regional Immunotherapy in Resectable Squamous Cell Lung Carcinoma. Analysis of a Randomized Study

N Roeslin et al. Cancer Immunol Immunother. .

Abstract

Patients with resectable squamous cell carcinoma were randomly allocated after surgery to receive either no further treatment (57 patients) or a single intrapleural injection of BCG (61 patients). No significant improvement in survival was observed in patients treated with BCG, even when their disease was staged as N0. There was a slight trend for the recurrence rate to be lower in patients classed as N0, but this was not significant.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Cancer Treat Rep. 1978 Nov;62(11):1671-5 - PubMed
    1. Lancet. 1980 Jan 5;1(8158):11-4 - PubMed
    1. Thorax. 1980 Oct;35(10):781-7 - PubMed
    1. J Thorac Cardiovasc Surg. 1976 Sep;72(3):333-8 - PubMed

Publication types

Feedback